Compare Ecolab Inc. (ECL) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? Ecolab Inc. trades at $282.11 (market cap $78.97B), while Regeneron Pharmaceuticals Inc trades at $748.66 (market cap $76.14B). The key difference: Ecolab Inc. and Regeneron Pharmaceuticals Inc are close in size by market cap, and Ecolab Inc. pays the higher dividend (1.04%). Which is the better fit depends on your goals — on Pluang, investors hold Ecolab Inc. for 90 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| ECL | REGN | |
|---|---|---|
Market Cap | $78.97B | $76.14B |
Volume | 974,947 | 500,239 |
Sector | Basic Materials | Health |
52-Week High | $308.35 | $852.03 |
52-Week Low | $245.73 | $557.73 |
Typical Hold Time | 90 Days | 107 Days |
Enterprise Value | $87.75B | $70.85B |
Dividend Yield | 1.04% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $282.21, up 1.48% today, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals with 2025 revenue of $16.08B, net income of $2.08B, and a 12.57% net margin. Recent news highlights its dividend aristocrat status and growth in high-tech segments, while institutional buying and insider purchases reflect confidence.
Outlook is positive given earnings beats, dividend reliability, and strategic expansions like the CoolIT deal, though rising debt and cost pressures pose risks. With a consensus price target of $326.38 implying 16% upside, ECL offers growth potential but requires monitoring of leverage and execution.
Regeneron Pharmaceuticals (REGN) trades at $747.21, up 0.69% with strong recent earnings beats. The stock shows bearish technical signals but maintains robust fundamentals with 84.86% gross margins and consistent revenue growth. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, providing significant upfront and milestone payments. Analyst consensus remains strongly bullish with 69% buy ratings and an $849.84 price target, representing 13.7% upside potential from current levels.
REGN presents a compelling growth story with strong profitability and strategic partnerships, though technical indicators suggest near-term consolidation. The expanded Sanofi collaboration and promising clinical trial data provide catalysts, while competition in key therapeutic areas and reliance on blockbuster drugs represent ongoing risks. Wall Street optimism remains high given the company's execution track record and pipeline potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
